MAY 09, 2022 3:00 AM PDT

A Gel Implant Protects from Cancer Recurrence

WRITTEN BY: Katie Kokolus

Following a successful course of cancer treatment, a patient may enter remission. Remission, classified as either partial or complete, is a condition where the patient exhibits reduced signs and symptoms of cancer.  Unfortunately, cancer can also become recurrent, meaning that it returns following treatment. 

Cancer recurrence occurs when a few rogue cancer cells remain in the body following treatment.  Because of the growth properties of cancer cells, only a small number of cells need to survive to grow into a new, recurrent cancer.  Since it only takes a few cells, the cancer can easily be missed on follow-up screening, but it still has the potential to grow and multiply to detectable cancer. 

Recurrent cancer is characterized by how far it has spread from the original site.  A local recurrence arises at or very close to the original cancer site.  Regional recurrences develop in the lymph nodes near the original cancer.  Distant recurrence occurs when the cancer has spread to organs or tissues far from the original cancer site. 

Cancer recurrence rates differ based on the type of cancer, treatment, and patient demographics.  The uncertainty stemming from the possibility of recurrence is a major concern for cancer survivors and their families.  This has focused an avenue of oncology research on developing methods to prevent cancer recurrence.  One exciting study, recently published in Nature Communications, has found that hydrogels loaded with drugs implanted during tumor removal surgery demonstrate significant benefit in in vivo mouse models.

The research team loaded hydrogels with two important drug compounds: Pexidartinib (PLX) and anti-programmed cell death protein 1 (αPD-1) antibody.  PLX blocks colony-stimulating factor 1 receptors (CSF1R) which in turn depletes immunosuppressive cells.  Because immunosuppressive cells hinder the anti-tumor immune response, decreasing their presence boosts immunity.  The elimination of these immunosuppressive cells promotes infiltration of cytotoxic T lymphocytes (CTLs), the immune cells responsible for killing cancer cells.  Importantly, the influx of CTLs primes the tumor microenvironment for optimal αPD-1 responsiveness. 

The study investigated the effectiveness of the hydrogel inserts in various mouse cancer models prone to cancer recurrence, including sarcoma (S180), melanoma (B16F10), colon cancer (CT26), and triple-negative breast cancer (4T1) models.  Tumor recurrence rates were reduced in all four models.  Further, the study demonstrated prolonged survival of mice implanted with hydrogels loaded with both PLX and αPD-1.  In addition to the anti-tumor efficacy demonstrated in this study, the hydrogel method also allows for local administration of the drugs usually given systemically.  Local delivery methods limit side effects that can develop toxicities on healthy tissue.  The authors suggest that the method developed in this study could be applied to additional drugs and may potentially boost the efficacy of other cancer immunotherapy approaches.

 

Sources: Oncology, Nat Commun

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
JAN 25, 2022
Immunology
Lung Cancer Vaccine Goes on Trial
JAN 25, 2022
Lung Cancer Vaccine Goes on Trial
Vaccines have been a hot topic in the headlines—blueprints that train the immune system to target a disease-causin ...
FEB 03, 2022
Immunology
Violet Extract Boosts Brain Cancer Drug's Performance
FEB 03, 2022
Violet Extract Boosts Brain Cancer Drug's Performance
Cyclotides are small, ring-shaped proteins produced by plants to defend themselves from certain insect pests and bacteri ...
JAN 31, 2022
Cancer
New Study Links Gene Mutations that Increase Breast Cancer Risk to Additional Cancers
JAN 31, 2022
New Study Links Gene Mutations that Increase Breast Cancer Risk to Additional Cancers
A genetic variant is a permanent change in the DNA sequence that makes up a gene.  While genetic variants often res ...
MAR 10, 2022
Drug Discovery & Development
Drug Equipped with Iron Sensor Halts Cancer Tumor Growth
MAR 10, 2022
Drug Equipped with Iron Sensor Halts Cancer Tumor Growth
A modified version of an FDA-approved drug can halt tumor growth driven by mutations in the RAS gene, which are notoriou ...
MAR 14, 2022
Cancer
Expanded Approval for the PD-1 Blocking Immunotherapy Opdivo
MAR 14, 2022
Expanded Approval for the PD-1 Blocking Immunotherapy Opdivo
Over the past decade, immunotherapy drugs known as immune checkpoint inhibitors have emerged as a promising an ...
MAY 12, 2022
Cancer
Crisis in Ukraine Disrupts Delivery of Critical Cancer Care
MAY 12, 2022
Crisis in Ukraine Disrupts Delivery of Critical Cancer Care
Many factors including the type of cancer, pathologic stage, and the general health and demographics of the patient, dic ...
Loading Comments...